Tegatrabetan

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug NameTegatrabetan
Drug Alias NameTegatrabetan - BetaCat PharmaceuticalsTegavivintBC-2059APL-121
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCatenin beta 1 inhibitorsWnt signalling pathway inhibitors
TargetsCatenin beta 1
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesAllergan Plc
China Registration ClassN/A

Develop Information

Active CompaniesApollomics IncHonorhealth Research InstituteNational Cancer Institute +[8] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[23] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A